[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540736":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":28,"locations":34,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Roswell Park Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Borderline Resectable (Cohort A)",null,"Pathological response of Patients with borderline resectable disease (per NCCD Criteria) treated with standard care chemotherapy",[13],"Other: Blood sample",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients with Resectable (Cohort B)","Pathological response of Patients with resectable disease (per NCCN criteria) treated with standard care chemotherapy",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Blood sample","To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients",[9,15],[24],{"name":25,"affiliation":26,"role":27},"Christos Fountilas, MD","Roswell Park Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Christos Fountzilas, MD","CONTACT","716-845-2300","Christos.Fountzilas@roswellpark.org",[35,48],{"facility":26,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":10},"RECRUITING","Buffalo","New York","14263","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-78.87837,42.88645,{"lat":46,"lon":45},{"facility":49,"status":36,"city":50,"state":38,"zip":51,"country":40,"countryCode":41,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Good Samaritan University Hospital","West Islip","11795",{"type":43,"coordinates":53},[54,55],-73.30623,40.70621,{"lat":55,"lon":54},[58,61],{"name":59,"role":31,"phone":60,"phoneExt":10,"email":10},"John Loscalzo, MD","631-417-8600",{"name":59,"role":27,"phone":10,"phoneExt":10,"email":10},{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100540736","ai-derived-biomarker-to-select-neoadjuvant-treatment-for-borderline-resectable-pancreatic-ductal-adenocarcinoma-100540736",false,"NCT06320717","AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma","A Retrospective\u002FProspective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Have histologically or cytologically confirmed PDAC that is borderline resectable (BR) (Cohort A) OR have histologically or cytologically confirmed PDAC that is resectable (Cohort B) using the National Comprehensive Cancer Network criteria \\[35\\].\n* Availability of archival tumor tissue (diagnostic for PDAC) required\n* Have a documented ECOG Performance Status of ≤ 1\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form (ICF) prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Has received prior systemic treatment (standard of care or experimental) for PDAC\n* Participant has a concurrent malignancy requiring active treatment during the study.","ALL","18 Years",{"count":74,"type":75},100,"ESTIMATED","OBSERVATIONAL","To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel.\n\nThe information collected will be used to determine if there are any \"biomarkers\" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.",[79],"Pancreatic Ductal Adenocarcinoma","2026-07-22",{"date":82,"type":83},"2026-07-23","ACTUAL",{"date":85,"type":83},"2024-01-02",{"date":87,"type":75},"2026-12-02",{"name":5,"class":6},2]